HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced its second-quarter 2026 financial and operational results, highlighting significant advancements in its heart attack detection program and an extended cash runway into 2027. The company reported a net loss of $5 million, or $0.10 per share, for the quarter ended June 30, 2026, consistent with the prior year's net loss of $5 million, or $0.15 per share. Cash, cash equivalents, and restricted cash stood at $8.8 million as of June 30, 2026, and the company expects full-year 2026 net operating cash outflow to be below $14 million, ensuring sufficient capital to fund operations into 2027.
HeartBeam is developing a cable-free device that collects ECG signals in 3D and synthesizes them into a standard 12-lead ECG. This technology has received FDA clearance for arrhythmia assessment and for the 12-lead ECG synthesis software. The company is currently conducting two pivotal studies: the ALIGN-ACS pilot study, which has completed enrollment of 134 patients ahead of schedule, and the HEADSTART-ACS pilot study, which has surpassed 50% enrollment of its 500-patient target. Full results from ALIGN-ACS are expected to be presented at TCT 2026, a major cardiology conference.
In addition to clinical progress, HeartBeam has achieved several commercial milestones. The company completed a working prototype of its 12-lead ECG extended wear patch, signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients. These steps mark the initial commercial launch of its innovative technology.
The implications of these developments are significant for the cardiac care industry and for investors. HeartBeam's technology aims to enable early detection of heart attacks and other acute cardiac conditions outside of traditional medical facilities, potentially reducing time to treatment and improving patient outcomes. The completion of the ALIGN-ACS study and progress in HEADSTART-ACS could provide the clinical evidence needed to support broader adoption and regulatory approvals. Furthermore, the extended cash runway into 2027 provides the company with the financial stability to pursue its strategic goals without immediate fundraising pressure.
For business and technology leaders, HeartBeam's progress underscores the growing trend of decentralized healthcare and the integration of advanced diagnostics into portable devices. The ability to synthesize a 12-lead ECG from a small, wearable device could revolutionize how cardiac conditions are monitored and managed, offering opportunities for cost savings and improved patient care. As the company moves forward, its success will depend on regulatory clearances, clinical validation, and market acceptance.
HeartBeam's latest news and updates are available in the company's newsroom at https://ibn.fm/BEAT. For more information about the company's cleared indications for use, visit https://www.heartbeam.com/indications.
